The Black-MSM PrEP gap
PrEP (pre-exposure prophylaxis for HIV) has been FDA-approved since 2012. CDC estimates that approximately 30% of Americans who would benefit from PrEP are receiving it, but uptake among Black MSM is materially lower than among white MSM despite Black MSM accounting for the largest share of new HIV diagnoses. The gap is structural: clinic-access friction, provider awareness, and the financial coordination required to navigate insurance + manufacturer assistance.
How Mistr addresses it
Mistr is built around removing every step that creates drop-off in the PrEP-uptake funnel. The intake is online and fast. The financial coordination (insurance + Gilead Advancing Access) is handled by Mistr's billing team, so most users pay $0 out of pocket. Quarterly labs are coordinated through partner labs near the patient. Shipping and billing are confidential. Founder Tristan Schukraft has been vocal about designing the service for the populations with the largest access gaps.
What it covers
PrEP initiation (Truvada, Descovy, or Apretude depending on candidacy), ongoing monitoring (kidney function, HIV status, STI screening at the same lab visit), and if HIV infection occurs, a transition pathway to HIV treatment with an in-network provider. Sexual-health counseling is available within the platform.
How to start
Complete the online intake including a candidacy assessment (any condomless sex with a partner of unknown HIV status in the last 6 months qualifies most adults). The platform handles insurance verification or coordinates Gilead Advancing Access if you are uninsured. Initial labs are scheduled at a partner lab near you; PrEP starts after labs confirm eligibility, typically within 7-14 days.